中裕新藥股份有限公司
中裕新藥股份有限公司（TaiMed Biologics Inc.）開發與商業化用於治療及預防感染性疾病的藥物。公司銷售用於愛滋病（HIV）治療的單株抗體藥物「Trogarzo」。目前正開發 HIV 預防用抗體 TMB-365 以及抗癌用抗體藥物複合體。公司成立於 2007 年，總部位於台灣台北。
今日上漲 7.39%，股價站回短期均線。該股 RSI(6) 為 64.6，處於中性區間，短線無明顯超買超賣訊號。股價站上5日、20日、60日、120日均線。KD 指標中性（K=65.1）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 08-10 | +391 | 0 | +3 | +391 |
| 08-07 | -279 | 0 | +4 | -279 |
| 08-06 | -75 | 0 | 0 | -75 |
| 08-05 | +162 | 0 | +5 | +165 |
| 08-04 | +36 | 0 | 0 | +10 |
| 08-03 | +270 | 0 | +3 | +267 |
| 07-31 | -446 | 0 | +61 | -416 |
| 07-30 | +85 | 0 | +3 | +86 |
| 07-29 | +347 | 0 | +9 | +349 |
| 07-28 | +235 | 0 | +2 | +235 |
| 07-27 | +136 | 0 | +1 | +135 |
| 07-24 | -59 | 0 | +3 | -59 |
| 07-23 | -1 | 0 | +5 | 0 |
| 07-22 | -142 | 0 | +7 | -144 |
| 07-21 | -199 | 0 | +1 | -200 |
| 07-20 | +191 | 0 | +4 | +190 |
| 07-17 | -49 | 0 | +36 | -48 |
| 07-16 | -277 | 0 | +6 | -278 |
| 07-15 | -24 | 0 | +1 | -25 |
| 07-14 | -1 | 0 | +1 | -1 |
| 07-13 | -648 | 0 | +10 | -653 |
| 07-09 | -57 | 0 | +13 | -58 |
| 07-08 | -177 | 0 | +4 | -178 |
| 07-07 | -126 | 0 | +9 | -125 |
| 07-06 | -32 | 0 | +9 | -32 |
| 07-03 | +1,065 | 0 | +14 | +1,062 |
| 07-02 | -331 | 0 | +3 | -330 |
| 07-01 | -594 | 0 | +3 | -594 |
| 06-30 | -203 | 0 | +9 | -204 |
| 06-29 | -137 | 0 | 0 | -138 |
| 06-26 | -119 | 0 | +9 | -192 |
| 06-25 | -9 | 0 | +10 | -9 |
| 06-24 | -794 | 0 | +20 | -799 |
| 06-23 | +476 | 0 | +19 | +481 |
| 06-22 | +125 | 0 | +1 | +126 |
| 06-18 | +186 | 0 | +1 | +187 |
| 06-17 | +16 | 0 | +1 | +16 |
| 06-16 | -30 | 0 | +1 | -30 |
| 06-15 | -104 | 0 | +2 | -103 |
| 06-12 | -842 | 0 | +3 | -841 |
| 06-11 | -812 | 0 | +9 | -807 |
| 06-10 | +64 | 0 | +4 | +64 |
| 06-09 | -20 | 0 | +3 | -21 |
| 06-08 | +57 | 0 | +3 | +57 |
| 06-05 | -444 | 0 | +3 | -445 |
| 06-04 | -114 | 0 | +7 | -113 |
| 06-03 | -103 | 0 | +2 | -103 |
| 06-02 | -210 | 0 | +1 | -210 |
| 06-01 | +709 | 0 | +9 | +709 |
| 05-29 | +481 | 0 | +1 | +481 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 4723 萬 | -39.8% | +21.8% |
| 2026/03 | 7843 萬 | +57.6% | +0.5% |
| 2026/02 | 4977 萬 | +31.4% | +2.9% |
| 2026/01 | 3788 萬 | -48.3% | -24.0% |
| 2025/12 | 7333 萬 | +93.3% | +56.9% |
| 2025/11 | 3793 萬 | -1.9% | -33.7% |
| 2025/10 | 3864 萬 | -34.8% | -7.5% |
| 2025/09 | 5924 萬 | +17.1% | +35.0% |
| 2025/08 | 5060 萬 | +33.8% | +0.6% |
| 2025/07 | 3783 萬 | -30.5% | -14.6% |
| 2025/06 | 5445 萬 | +22.9% | +23.8% |
| 2025/05 | 4431 萬 | - | -3.1% |